Ten years ago, you quietly got a hair transplant and never spoke a word of it to anyone. Today it's a content genre.
Worldwide procedures rose from ~397,000 in 2014 to roughly 703,000 by 2021, per the International Society of Hair Restoration Surgery.
Patients are getting younger, too: In 2024, 95% of first-timers started between ages 20 and 35, and 44% planned to tell people about it.
The Tech That Made It Easy
The old "strip" method cut a band of scalp from the back of the head, leaving a long scar. The newer method, FUE, or follicular unit extraction, pulls follicles out one at a time with a tiny punch. No stitches, no linear scar, faster recovery.
In 2012, FUE was about a third of procedures. By 2024, it was 76.8%. Motorized punches, robots, and better graft handling turned a grueling surgery into a repeatable, almost assembly-line process.
That standardization is exactly what made Turkey emerge in the industry.
Turkey Built the Costco of Hairlines
FUE runs on skilled labor, and Turkey has it at scale, plus lower costs and a government push for health tourism. A 2,500-graft transplant averages about $2,700 there versus roughly $13,600 in the U.S. Packages usually bundle the hotel, airport pickup, and a translator.
Around 1 million people flew in for hair transplants in 2022, spending about $2 billion total. As a result, health-tourism revenue hit $3.02 billion in 2025.
From Medical Trip to Meme
The proof is on the plane. In September 2024, an Istanbul Airport clip of rows of bandaged scalps, captioned "Turkish Hairlines," went viral. The phrase stuck. In March 2026, Turkish users on X jokingly promised Spain free transplants as a "brother country" gesture.
Memes are free marketing. Every joke makes the procedure feel more normal, and going viral is the gift companies dream of.
The boom has a dark side, though. 59% of ISHRS members now report black-market clinics in their cities, up from 51% in 2021, and repeat surgeries rose to 6.9% of transplants. Quality control is the industry's biggest risk.
Where the Money Moves Next
What’s interesting is that the next big hair winners may not be surgeons. A transplant moves hair; it doesn't stop loss. Patients still need medication to keep what they have, and the drug pipeline is the busiest it's been in decades.
$MANE (Veradermics): We're bullish on this one. Its extended-release minoxidil pill won a second Phase 3 on Oct. 19 (28.6 to 36.4 new hairs/cm² vs. 6.6 for placebo). After a 500%+ run since its February IPO, expect big swings around 12-month data due later this year. If approved, it's the first new FDA hair-loss pill in roughly 30 years.
Cosmo Pharmaceuticals (SIX: COPN): The stock needs a commercial partner, and management has given no timeline. Long term, we are bullish. Jefferies sees up to $4 billion in peak sales for its clascoterone topical, with an FDA filing planned for early 2027.
$ABSI (Absci): Speculative. First hair-count data is due in the second half of 2026, so it's a binary event. Long term: high-upside. Two or three injections every six months would create a new category. Eli Lilly invested $40 million.
$HIMS (Hims & Hers): Weight loss drives the story now, and gross margin slid to 63.8%. When new hair drugs launch, young men will buy them through telehealth.
$VERO (Venus Concept): Avoid. Its ARTAS robot helped modernize the field, but cheap Turkish labor beat expensive robots. The company announced a voluntary Nasdaq delisting.
Looking Toward the Future
Hair restoration went from taboo to TikTok in a decade. Turkey won the surgery side on price and volume. The next decade's edge is pharma: the pill and the topical that protect the hairline people flew across the world for.
We favor drug developers with dated catalysts, keep position sizes small, and treat $ABSI as a lottery ticket.
This is not investment advice. Do your own research.
Sources
Sponsored by
Invest Alongside a Manager with a 40-Year Track Record
Private real estate has long been a cornerstone of institutional portfolios, but individual investors have often had limited access to the asset class - or have had to invest through pooled funds and intermediaries.
Lightstone DIRECT offers a different approach. Accredited investors can invest directly in select real estate opportunities alongside Lightstone, a vertically integrated owner/operator with more than four decades of experience and a $12 billion real estate portfolio.
We invest 20% or more of the equity in every offering, aligning our interests with yours from day one. Our in-house team oversees acquisitions, asset management, and investment execution, with property operations managed by Lightstone and, where appropriate, experienced third-party operators.
No blind funds. No intermediaries. Just direct partnership.
Accredited Investors only. $100k minimum investment.
This communication is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. Any such offer or solicitation will be made exclusively through the definitive offering documents. All investments involve risk of loss, including the potential loss of principal. Past performance is not a guarantee of future results. Any targeted returns or projections are forward-looking statements, are based on current assumptions, and are not guarantees of future performance. Actual results may differ materially.
For education only — not financial advice. BullBuzz™ by TRDR Media shares opinion and analysis, not recommendations to buy, sell, or hold any security. TRDR Media is not a registered investment adviser and does not manage or solicit funds. Trading and investing carry a substantial risk of loss and aren't suitable for everyone. Any prices, levels, or data may be delayed or estimated, and past results or prior calls don't guarantee future performance. You alone are responsible for your decisions. Consult a licensed financial advisor before trading.
